Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hutchmed China Ltd ADR (NQ: HCM )

14.20 -0.39 (-2.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 276,962
Open 14.45
Bid (Size) 13.80 (5)
Ask (Size) 14.20 (1)
Prev. Close 14.59
Today's Range 13.72 - 14.45
52wk Range 7.390 - 21.44
Shares Outstanding 864,775,340
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
From HUTCHMED (China) Limited
Via Globe NewsWire

Performance

YTD
-13.31%
-13.31%
1 Month
-9.84%
-9.84%
3 Month
-3.40%
-3.40%
6 Month
+49.47%
+49.47%
1 Year
-28.32%
-28.32%

More News

Read More
Why Miromatrix Medical Shares Are Trading Lower By 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
From HUTCHMED (China) Limited
Via Globe NewsWire
Lyft, BARK And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
Via Benzinga
Hutchmed Plans Strategic Focus Shift On Late-Stage Programs, Details Not Disclosed
Via Benzinga
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
HUTCHMED to Announce 2022 Final Results
From HUTCHMED (China) Limited
Via Globe NewsWire
Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday
Via Benzinga
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
Via Talk Markets
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
From HUTCHMED (China) Limited
Via Globe NewsWire
Constellation Brands, Walgreens, RPM International And Some Other Big Stocks Moving Lower On Thursday
Via Benzinga
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
From HUTCHMED (China) Limited
Via Globe NewsWire
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
From HUTCHMED (China) Limited
Via Globe NewsWire
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
From Prenetics Limited
Via Globe NewsWire
Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Deutsche Bank ADR Investor Conference: Presentations Now Available for On-Demand Viewing
From Virtual Investor Conferences
Via Globe NewsWire
Miniso Group, Monday.com And Other Big Gainers From Monday
Via Benzinga
HUTCHMED Announces Strategy to Focus on Late-Stage Pipeline Regulatory Approvals
From HUTCHMED (China) Limited
Via Globe NewsWire
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.